Detection and quantification of tumor-derived mutations in cell-free DNA (cfDNA) holds great potential for non-invasive tumor diagnosticsand molecular monitoring. We developed highly sensitive discriminatory multi-target digital droplet PCR (ddPCR) assays covering 14 KRAS and NRASS hotspot mutations
Circulating tumor DNA (ctDNA) is released from cancer cells and oncogenic mutations in ctDNA can be ...
Breast cancer is the leading cause of cancer-related deaths in women worldwide. Approximately 40% of...
Establishing the KRAS mutational status of tumor samples is essential to manage patients with colore...
Detection and quantification of tumor-derived mutations in cell-free DNA (cfDNA) holds great potentia...
Detection and quantification of tumor-derived KRAS and NRAS mutations in plasma cell-free DNA (cfDNA...
Droplet digital PCR (ddPCR) can be used to detect low frequency mutations in oncogene-driven lung ca...
Circulating tumour DNA (ctDNA) are short extracellular DNA fragments that have been explored by a nu...
International audienceBACKGROUND: Progress in the liquid biopsy field, combined with the development...
© 2015 Pender et al. This is an open access article distributed under the terms of the Creative Comm...
The detection of EGFR-sensitizing and EGFR-resistance mutations in advanced non-small-cell lung canc...
<div><p>Droplet digital PCR (ddPCR) can be used to detect low frequency mutations in oncogene-driven...
Measuring total cell-free DNA (cfDNA) or cancer-specific mutations herein has presented as new tools...
Enthusiasm has emerged for the potential of liquid biopsies to provide easily accessible genetic bio...
Cancer is one of the leading causes of death worldwide and remains a major public health challenge. ...
International audienceIn cancer research, the accuracy of the technology used for biomarkers detecti...
Circulating tumor DNA (ctDNA) is released from cancer cells and oncogenic mutations in ctDNA can be ...
Breast cancer is the leading cause of cancer-related deaths in women worldwide. Approximately 40% of...
Establishing the KRAS mutational status of tumor samples is essential to manage patients with colore...
Detection and quantification of tumor-derived mutations in cell-free DNA (cfDNA) holds great potentia...
Detection and quantification of tumor-derived KRAS and NRAS mutations in plasma cell-free DNA (cfDNA...
Droplet digital PCR (ddPCR) can be used to detect low frequency mutations in oncogene-driven lung ca...
Circulating tumour DNA (ctDNA) are short extracellular DNA fragments that have been explored by a nu...
International audienceBACKGROUND: Progress in the liquid biopsy field, combined with the development...
© 2015 Pender et al. This is an open access article distributed under the terms of the Creative Comm...
The detection of EGFR-sensitizing and EGFR-resistance mutations in advanced non-small-cell lung canc...
<div><p>Droplet digital PCR (ddPCR) can be used to detect low frequency mutations in oncogene-driven...
Measuring total cell-free DNA (cfDNA) or cancer-specific mutations herein has presented as new tools...
Enthusiasm has emerged for the potential of liquid biopsies to provide easily accessible genetic bio...
Cancer is one of the leading causes of death worldwide and remains a major public health challenge. ...
International audienceIn cancer research, the accuracy of the technology used for biomarkers detecti...
Circulating tumor DNA (ctDNA) is released from cancer cells and oncogenic mutations in ctDNA can be ...
Breast cancer is the leading cause of cancer-related deaths in women worldwide. Approximately 40% of...
Establishing the KRAS mutational status of tumor samples is essential to manage patients with colore...